Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Average (2016 - 2025)

Historic Equity Average for Cytosorbents (CTSO) over the last 14 years, with Q3 2025 value amounting to $10.3 million.

  • Cytosorbents' Equity Average fell 3260.17% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 3260.17%. This contributed to the annual value of $17.3 million for FY2024, which is 4123.27% down from last year.
  • As of Q3 2025, Cytosorbents' Equity Average stood at $10.3 million, which was down 3260.17% from $13.1 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Equity Average ranged from a high of $78.2 million in Q1 2021 and a low of $10.3 million during Q3 2025
  • Moreover, its 5-year median value for Equity Average was $27.2 million (2023), whereas its average is $36.3 million.
  • In the last 5 years, Cytosorbents' Equity Average skyrocketed by 53269.13% in 2021 and then plummeted by 5009.05% in 2023.
  • Over the past 5 years, Cytosorbents' Equity Average (Quarter) stood at $66.6 million in 2021, then tumbled by 44.05% to $37.3 million in 2022, then crashed by 43.24% to $21.1 million in 2023, then crashed by 42.66% to $12.1 million in 2024, then fell by 15.03% to $10.3 million in 2025.
  • Its Equity Average was $10.3 million in Q3 2025, compared to $13.1 million in Q2 2025 and $12.8 million in Q1 2025.